Marshall Financial Group LLC Invests $691,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Marshall Financial Group LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 970 shares of the biopharmaceutical company’s stock, valued at approximately $691,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Adirondack Trust Co. grew its holdings in shares of Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after purchasing an additional 10 shares in the last quarter. UMB Bank n.a. raised its stake in Regeneron Pharmaceuticals by 1.1% in the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock valued at $955,000 after purchasing an additional 10 shares in the last quarter. Trust Co. of Vermont lifted its position in Regeneron Pharmaceuticals by 8.3% during the third quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock worth $165,000 after purchasing an additional 12 shares during the period. Nvwm LLC grew its stake in Regeneron Pharmaceuticals by 1.4% during the third quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock worth $1,039,000 after buying an additional 14 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 3.6% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 434 shares of the biopharmaceutical company’s stock valued at $456,000 after buying an additional 15 shares during the period. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the subject of a number of recent analyst reports. Royal Bank of Canada cut their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Citigroup cut their target price on Regeneron Pharmaceuticals from $895.00 to $795.00 and set a “neutral” rating for the company in a research note on Tuesday, January 14th. Barclays decreased their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Morgan Stanley dropped their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Finally, Piper Sandler decreased their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,015.38.

Regeneron Pharmaceuticals Trading Down 2.7 %

NASDAQ REGN opened at $675.79 on Friday. The firm has a market capitalization of $74.26 billion, a PE ratio of 16.72, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10. The business’s 50-day moving average price is $727.19 and its two-hundred day moving average price is $937.77. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $666.25 and a 12 month high of $1,211.20.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.